Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 126

1.

Dual Vasopressin V1a/V2 Antagonism: The Next Step in Neurohormonal Modulation in Patients With Heart Failure?

Goldsmith SR, Udelson JE, Gheorghiade M.

J Card Fail. 2018 Feb;24(2):112-114. doi: 10.1016/j.cardfail.2017.12.011. Epub 2018 Jan 9.

PMID:
29329950
2.

Neurohormonal Imbalance: A Neglected Problem-And Potential Therapeutic Target-In Acute Heart Failure.

Goldsmith SR, Bart BA, Piña IL.

Curr Probl Cardiol. 2017 Dec 16. pii: S0146-2806(17)30188-3. doi: 10.1016/j.cpcardiol.2017.12.002. [Epub ahead of print]

PMID:
29310997
3.

Donor-lymphocyte infusion following haploidentical hematopoietic cell transplantation with peripheral blood stem cell grafts and PTCy.

Goldsmith SR, Slade M, DiPersio JF, Westervelt P, Schroeder MA, Gao F, Romee R.

Bone Marrow Transplant. 2017 Dec;52(12):1623-1628. doi: 10.1038/bmt.2017.193. Epub 2017 Oct 16.

PMID:
29035393
4.

Prognostic importance of sodium level trajectory in acute heart failure.

Matsue Y, Yoshioka K, Suzuki M, Torii S, Yamaguchi S, Fukamizu S, Ono Y, Fujii H, Kitai T, Nishioka T, Sugi K, Onishi Y, Noda M, Kagiyama N, Satoh Y, Yoshida K, Goldsmith SR.

Heart Vessels. 2017 Dec;32(12):1498-1505. doi: 10.1007/s00380-017-1020-5. Epub 2017 Jul 11.

PMID:
28698994
5.

Early treatment with tolvaptan improves diuretic response in acute heart failure with renal dysfunction.

Matsue Y, Ter Maaten JM, Suzuki M, Torii S, Yamaguchi S, Fukamizu S, Ono Y, Fujii H, Kitai T, Nishioka T, Sugi K, Onishi Y, Noda M, Kagiyama N, Satoh Y, Yoshida K, van der Meer P, Damman K, Voors AA, Goldsmith SR.

Clin Res Cardiol. 2017 Oct;106(10):802-812. doi: 10.1007/s00392-017-1122-1. Epub 2017 May 24.

6.

The effect of targeted temperature management on QT and corrected QT intervals in patients with cardiac arrest.

Rosol Z, Miranda DF, Sandoval Y, Bart BA, Smith SW, Goldsmith SR.

J Crit Care. 2017 Jun;39:182-184. doi: 10.1016/j.jcrc.2017.02.030. Epub 2017 Feb 22.

PMID:
28284166
7.

Future Study With Tolvaptan in Acute Heart Failure.

Goldsmith SR.

J Am Coll Cardiol. 2017 Jan 31;69(4):467. doi: 10.1016/j.jacc.2016.11.032. No abstract available.

8.

Corrigendum to "Clinical Effectiveness of Tolvaptan in Patients With Acute Heart Failure and Renal Dysfunction" Journal of Cardiac Failure, Vol. 22, No. 6, June 2016, pp. 423-432.

Matsue Y, Suzuki M, Torii S, Yamaguchi S, Fukamizu S, Ono Y, Fujii H, Kitai T, Nishioka T, Sugi K, Onishi Y, Noda M, Kagiyama N, Satoh Y, Yoshida K, Goldsmith SR.

J Card Fail. 2016 Nov;22(11):941. doi: 10.1016/j.cardfail.2016.07.434. Epub 2016 Jul 29. No abstract available.

PMID:
27481596
9.

Cytomegalovirus viremia, disease, and impact on relapse in T-cell replete peripheral blood haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide.

Goldsmith SR, Slade M, DiPersio JF, Westervelt P, Lawrence SJ, Uy GL, Abboud CN, Vij R, Schroeder MA, Fehniger TA, Dubberke ER, Trinkaus K, Romee R.

Haematologica. 2016 Nov;101(11):e465-e468. Epub 2016 Jul 21. No abstract available.

10.

Prognostic impact of early treatment with tolvaptan in patients with acute heart failure and renal dysfunction.

Matsue Y, Suzuki M, Torii S, Yamaguchi S, Fukamizu S, Ono Y, Fujii H, Kitai T, Nishioka T, Sugi K, Onishi Y, Noda M, Kagiyama N, Satoh Y, Yoshida K, Goldsmith SR.

Int J Cardiol. 2016 Oct 15;221:188-93. doi: 10.1016/j.ijcard.2016.07.063. Epub 2016 Jul 5.

PMID:
27404673
11.

A new approach to treatment of acute heart failure.

Goldsmith SR.

J Cardiol. 2016 May;67(5):395-8. doi: 10.1016/j.jjcc.2016.02.004. Epub 2016 Mar 3. Review.

12.

Clinical Effectiveness of Tolvaptan in Patients With Acute Heart Failure and Renal Dysfunction.

Matsue Y, Suzuki M, Torii S, Yamaguchi S, Fukamizu S, Ono Y, Fujii H, Kitai T, Nishioka T, Sugi K, Onishi Y, Noda M, Kagiyama N, Satoh Y, Yoshida K, Goldsmith SR.

J Card Fail. 2016 Jun;22(6):423-32. doi: 10.1016/j.cardfail.2016.02.007. Epub 2016 Feb 23. Erratum in: J Card Fail. 2016 Nov;22(11):941.

PMID:
26915749
13.

Contrasting acute and chronic effects of tolvaptan on serum osmolality in the EVEREST trial.

Vaduganathan M, Goldsmith SR, Senni M, Butler J, Gheorghiade M.

Eur J Heart Fail. 2016 Feb;18(2):185-91. doi: 10.1002/ejhf.415. Epub 2015 Oct 7.

14.

Relief and Recurrence of Congestion During and After Hospitalization for Acute Heart Failure: Insights From Diuretic Optimization Strategy Evaluation in Acute Decompensated Heart Failure (DOSE-AHF) and Cardiorenal Rescue Study in Acute Decompensated Heart Failure (CARESS-HF).

Lala A, McNulty SE, Mentz RJ, Dunlay SM, Vader JM, AbouEzzeddine OF, DeVore AD, Khazanie P, Redfield MM, Goldsmith SR, Bart BA, Anstrom KJ, Felker GM, Hernandez AF, Stevenson LW.

Circ Heart Fail. 2015 Jul;8(4):741-8. doi: 10.1161/CIRCHEARTFAILURE.114.001957. Epub 2015 Jun 3.

15.

Effects of Xanthine Oxidase Inhibition in Hyperuricemic Heart Failure Patients: The Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients (EXACT-HF) Study.

Givertz MM, Anstrom KJ, Redfield MM, Deswal A, Haddad H, Butler J, Tang WH, Dunlap ME, LeWinter MM, Mann DL, Felker GM, O'Connor CM, Goldsmith SR, Ofili EO, Saltzberg MT, Margulies KB, Cappola TP, Konstam MA, Semigran MJ, McNulty SE, Lee KL, Shah MR, Hernandez AF; NHLBI Heart Failure Clinical Research Network.

Circulation. 2015 May 19;131(20):1763-71. doi: 10.1161/CIRCULATIONAHA.114.014536. Epub 2015 Apr 14.

16.

Decongestion strategies and renin-angiotensin-aldosterone system activation in acute heart failure.

Mentz RJ, Stevens SR, DeVore AD, Lala A, Vader JM, AbouEzzeddine OF, Khazanie P, Redfield MM, Stevenson LW, O'Connor CM, Goldsmith SR, Bart BA, Anstrom KJ, Hernandez AF, Braunwald E, Felker GM.

JACC Heart Fail. 2015 Feb;3(2):97-107. doi: 10.1016/j.jchf.2014.09.003. Epub 2014 Oct 31.

17.

The reply.

Verbalis JG, Goldsmith SR, Greenberg A, Korzelius C, Schrier RW, Sterns RH, Thompson CJ.

Am J Med. 2014 Jul;127(7):e31-2. doi: 10.1016/j.amjmed.2014.03.022. No abstract available.

PMID:
24970609
18.

Decongestive therapy and renal function in acute heart failure: time for a new approach?

Goldsmith SR, Bart BA, Burnett J.

Circ Heart Fail. 2014 May;7(3):531-5. doi: 10.1161/CIRCHEARTFAILURE.113.000828. No abstract available.

19.

Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial.

Chen HH, Anstrom KJ, Givertz MM, Stevenson LW, Semigran MJ, Goldsmith SR, Bart BA, Bull DA, Stehlik J, LeWinter MM, Konstam MA, Huggins GS, Rouleau JL, O'Meara E, Tang WH, Starling RC, Butler J, Deswal A, Felker GM, O'Connor CM, Bonita RE, Margulies KB, Cappola TP, Ofili EO, Mann DL, Dávila-Román VG, McNulty SE, Borlaug BA, Velazquez EJ, Lee KL, Shah MR, Hernandez AF, Braunwald E, Redfield MM; NHLBI Heart Failure Clinical Research Network.

JAMA. 2013 Dec 18;310(23):2533-43. doi: 10.1001/jama.2013.282190.

20.

Vasopressin receptor antagonists: from pivotal trials to current practice.

Kalra A, Maharaj V, Goldsmith SR.

Curr Heart Fail Rep. 2014 Mar;11(1):10-8. doi: 10.1007/s11897-013-0175-3. Review.

PMID:
24197791
21.

Diagnosis, evaluation, and treatment of hyponatremia: expert panel recommendations.

Verbalis JG, Goldsmith SR, Greenberg A, Korzelius C, Schrier RW, Sterns RH, Thompson CJ.

Am J Med. 2013 Oct;126(10 Suppl 1):S1-42. doi: 10.1016/j.amjmed.2013.07.006.

PMID:
24074529
22.

Hyponatremia in heart failure: time for a trial.

Goldsmith SR.

J Card Fail. 2013 Jun;19(6):398-400. doi: 10.1016/j.cardfail.2013.04.003. Epub 2013 May 14. No abstract available. Erratum in: J Card Fail. 2013 Sep;19(9):663.

PMID:
23743488
23.

Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial.

Redfield MM, Chen HH, Borlaug BA, Semigran MJ, Lee KL, Lewis G, LeWinter MM, Rouleau JL, Bull DA, Mann DL, Deswal A, Stevenson LW, Givertz MM, Ofili EO, O'Connor CM, Felker GM, Goldsmith SR, Bart BA, McNulty SE, Ibarra JC, Lin G, Oh JK, Patel MR, Kim RJ, Tracy RP, Velazquez EJ, Anstrom KJ, Hernandez AF, Mascette AM, Braunwald E; RELAX Trial.

JAMA. 2013 Mar 27;309(12):1268-77. doi: 10.1001/jama.2013.2024.

24.

Appendicitis presenting as cardiac tamponade.

Sandoval Y, Williams DM, Goldsmith SR.

J Thorac Cardiovasc Surg. 2013 Jul;146(1):228. doi: 10.1016/j.jtcvs.2013.01.010. Epub 2013 Feb 8. No abstract available.

25.

Association of arginine vasopressin levels with outcomes and the effect of V2 blockade in patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial.

Lanfear DE, Sabbah HN, Goldsmith SR, Greene SJ, Ambrosy AP, Fought AJ, Kwasny MJ, Swedberg K, Yancy CW, Konstam MA, Maggioni AP, Zannad F, Gheorghiade M; EVEREST trial investigators.

Circ Heart Fail. 2013 Jan;6(1):47-52. doi: 10.1161/CIRCHEARTFAILURE.112.970012. Epub 2012 Dec 12.

26.

Hyponatremia and outcomes in patients with heart failure.

Goldsmith SR.

Heart. 2012 Dec;98(24):1761-2. doi: 10.1136/heartjnl-2012-302854. No abstract available.

PMID:
23204533
27.

Obesity and the response to intensified diuretic treatment in decompensated heart failure: a DOSE trial substudy.

Gupta A, Braunwald E, McNulty S, Felker GM, Gilbert EM, Alharethi R, Lee KL, Anstrom KJ, Redfield MM, Goldsmith SR, O'Connor CM, Bull DA, Stehlik J, Litwin SE.

J Card Fail. 2012 Nov;18(11):837-44. doi: 10.1016/j.cardfail.2012.09.005.

28.

Ultrafiltration in decompensated heart failure with cardiorenal syndrome.

Bart BA, Goldsmith SR, Lee KL, Givertz MM, O'Connor CM, Bull DA, Redfield MM, Deswal A, Rouleau JL, LeWinter MM, Ofili EO, Stevenson LW, Semigran MJ, Felker GM, Chen HH, Hernandez AF, Anstrom KJ, McNulty SE, Velazquez EJ, Ibarra JC, Mascette AM, Braunwald E; Heart Failure Clinical Research Network.

N Engl J Med. 2012 Dec 13;367(24):2296-304. doi: 10.1056/NEJMoa1210357. Epub 2012 Nov 6.

29.

Prognostic implications of renal dysfunction in patients hospitalized with heart failure: data from the last decade of clinical investigations.

Brandimarte F, Vaduganathan M, Mureddu GF, Cacciatore G, Sabbah HN, Fonarow GC, Goldsmith SR, Butler J, Fedele F, Gheorghiade M.

Heart Fail Rev. 2013 Mar;18(2):167-76. doi: 10.1007/s10741-012-9317-z. Review.

PMID:
22572909
30.

Cardiorenal rescue study in acute decompensated heart failure: rationale and design of CARRESS-HF, for the Heart Failure Clinical Research Network.

Bart BA, Goldsmith SR, Lee KL, Redfield MM, Felker GM, O'Connor CM, Chen HH, Rouleau JL, Givertz MM, Semigran MJ, Mann D, Deswal A, Bull DA, Lewinter MM, Braunwald E.

J Card Fail. 2012 Mar;18(3):176-82. doi: 10.1016/j.cardfail.2011.12.009. Epub 2012 Feb 2.

31.

Renal effects of conivaptan, furosemide, and the combination in patients with chronic heart failure.

Goldsmith SR, Gilbertson DT, Mackedanz SA, Swan SK.

J Card Fail. 2011 Dec;17(12):982-9. doi: 10.1016/j.cardfail.2011.08.012. Epub 2011 Oct 6.

PMID:
22123359
32.

Found in translation.

Sobotka PA, Goldsmith SR.

J Card Fail. 2011 Oct;17(10):804-5. doi: 10.1016/j.cardfail.2011.09.001. No abstract available.

PMID:
21962417
33.

Tolvaptan for the treatment of heart failure: a review of the literature.

Ambrosy A, Goldsmith SR, Gheorghiade M.

Expert Opin Pharmacother. 2011 Apr;12(6):961-76. doi: 10.1517/14656566.2011.567267. Epub 2011 Mar 15. Review.

PMID:
21401442
34.

Diuretic strategies in patients with acute decompensated heart failure.

Felker GM, Lee KL, Bull DA, Redfield MM, Stevenson LW, Goldsmith SR, LeWinter MM, Deswal A, Rouleau JL, Ofili EO, Anstrom KJ, Hernandez AF, McNulty SE, Velazquez EJ, Kfoury AG, Chen HH, Givertz MM, Semigran MJ, Bart BA, Mascette AM, Braunwald E, O'Connor CM; NHLBI Heart Failure Clinical Research Network.

N Engl J Med. 2011 Mar 3;364(9):797-805. doi: 10.1056/NEJMoa1005419.

35.

Treatment options for hyponatremia in heart failure.

Goldsmith SR.

Congest Heart Fail. 2010 Jul;16 Suppl 1:S15-8. doi: 10.1111/j.1751-7133.2010.00164.x. Review.

36.

The sympathorenal axis in hypertension and heart failure.

Goldsmith SR, Sobotka PA, Bart BA.

J Card Fail. 2010 May;16(5):369-73. doi: 10.1016/j.cardfail.2009.12.022. Epub 2010 Feb 20.

PMID:
20447571
37.

Congestion as a therapeutic target in acute heart failure syndromes.

Goldsmith SR, Brandimarte F, Gheorghiade M.

Prog Cardiovasc Dis. 2010 Mar-Apr;52(5):383-92. doi: 10.1016/j.pcad.2009.11.005. Review.

PMID:
20226956
38.

Results of the Prospective Minnesota Study of ECHO/TDI in Cardiac Resynchronization Therapy (PROMISE-CRT) study.

Bank AJ, Kaufman CL, Kelly AS, Burns KV, Adler SW, Rector TS, Goldsmith SR, Olivari MT, Tang C, Nelson L, Metzig A; PROMISE-CRT Investigators.

J Card Fail. 2009 Jun;15(5):401-9. doi: 10.1016/j.cardfail.2008.12.009. Epub 2009 Feb 8.

PMID:
19477400
39.

Efficacy and safety of the vasopressin V1A/V2-receptor antagonist conivaptan in acute decompensated heart failure: a dose-ranging pilot study.

Goldsmith SR, Elkayam U, Haught WH, Barve A, He W.

J Card Fail. 2008 Oct;14(8):641-7. doi: 10.1016/j.cardfail.2008.06.003. Epub 2008 Jul 10.

PMID:
18926434
40.

Treatment options for hyponatremia in heart failure.

Goldsmith SR.

Heart Fail Rev. 2009 Jun;14(2):65-73. doi: 10.1007/s10741-008-9110-1. Epub 2008 Sep 6. Review.

PMID:
18777208
41.

Renal function and ultrafiltration.

Bart BA, Goldsmith SR, Boyle A, Costanzo MR.

J Card Fail. 2008 Aug;14(6):533-4; author reply 534. doi: 10.1016/j.cardfail.2008.03.005. Epub 2008 May 27. No abstract available.

PMID:
18672204
42.

Ultrafiltration for cardiorenal syndrome.

Bart BA, Walsh MM, Blake D, Goldsmith SR.

J Card Fail. 2008 Aug;14(6):531-2; author reply 532-3. doi: 10.1016/j.cardfail.2008.03.002. Epub 2008 May 27. No abstract available.

PMID:
18672202
43.

Type 5 phosphodiesterase inhibition in heart failure: the next step.

Goldsmith SR.

J Am Coll Cardiol. 2007 Nov 27;50(22):2145-7. Epub 2007 Nov 13. No abstract available.

44.

Hyponatremia treatment guidelines 2007: expert panel recommendations.

Verbalis JG, Goldsmith SR, Greenberg A, Schrier RW, Sterns RH.

Am J Med. 2007 Nov;120(11 Suppl 1):S1-21.

PMID:
17981159
45.

Treating hyponatremia in heart failure.

Goldsmith SR.

Curr Cardiol Rep. 2006 May;8(3):204-10. Review.

PMID:
17552085
46.

The role of vasopressin in congestive heart failure.

Goldsmith SR.

Cleve Clin J Med. 2006 Sep;73 Suppl 3:S19-23. Review.

PMID:
16970149
47.
48.

Vasopressin receptor antagonists: mechanisms of action and potential effects in heart failure.

Goldsmith SR.

Cleve Clin J Med. 2006 Jun;73 Suppl 2:S20-3; discussion S30-3. Review.

PMID:
16786909
49.

Ultrafiltration versus usual care for hospitalized patients with heart failure: the Relief for Acutely Fluid-Overloaded Patients With Decompensated Congestive Heart Failure (RAPID-CHF) trial.

Bart BA, Boyle A, Bank AJ, Anand I, Olivari MT, Kraemer M, Mackedanz S, Sobotka PA, Schollmeyer M, Goldsmith SR.

J Am Coll Cardiol. 2005 Dec 6;46(11):2043-6. Epub 2005 Nov 4.

50.

Vasopressin antagonism in heart failure.

Goldsmith SR, Gheorghiade M.

J Am Coll Cardiol. 2005 Nov 15;46(10):1785-91. Epub 2005 Oct 21. Review.

Supplemental Content

Loading ...
Support Center